Łukasz Matusiak1, Justyna Szczęch2, Andrzej Bieniek2, Danuta Nowicka-Suszko2, Jacek C Szepietowski2. 1. Department of Dermatology, Venereology, and Allergology, Wroclaw Medical University, Wrocław, Poland. Electronic address: luke71@interia.pl. 2. Department of Dermatology, Venereology, and Allergology, Wroclaw Medical University, Wrocław, Poland.
Abstract
BACKGROUND: Biologics seem to offer a promising nonsurgical approach in hidradenitis suppurativa (HS), especially in disease with highly pronounced inflammation. Recent studies revealed increased expression of a broad range of cytokines in lesional HS skin, including interleukin (IL)-17. OBJECTIVE: This study was undertaken to determine IL-17 serum levels in this group of patients. METHODS: Our study was conducted on a group of 86 patients between 16 and 72 years of age with HS. A total of 86 matched healthy volunteers constituted the control group. Enzyme-linked immunosorbent assay kits were used to quantify IL-17 serum concentration. RESULTS: The mean IL-17 serum level of patients with HS was 3.68 ± 2.08 pg/mL, which was significantly elevated (P < .0001) compared with that found in healthy volunteers (2.5 ± 1.11 pg/mL). Moreover, there was a tendency toward higher serum concentrations of IL-17 in patients with more advanced disease (P = .005). Disease duration; patient sex, age, and body mass index; and smoking habits were not determining factors for IL-17 serum concentration. LIMITATIONS: Hospital-based study population was a limitation, as was a lack of posttreatment assessment. CONCLUSION: In light of our findings and literature on increased expression of IL-17 in HS lesions, evaluating the clinical effectiveness of using anti-IL-17 agents in the treatment of patients with HS is justified.
BACKGROUND: Biologics seem to offer a promising nonsurgical approach in hidradenitis suppurativa (HS), especially in disease with highly pronounced inflammation. Recent studies revealed increased expression of a broad range of cytokines in lesional HS skin, including interleukin (IL)-17. OBJECTIVE: This study was undertaken to determine IL-17 serum levels in this group of patients. METHODS: Our study was conducted on a group of 86 patients between 16 and 72 years of age with HS. A total of 86 matched healthy volunteers constituted the control group. Enzyme-linked immunosorbent assay kits were used to quantify IL-17 serum concentration. RESULTS: The mean IL-17 serum level of patients with HS was 3.68 ± 2.08 pg/mL, which was significantly elevated (P < .0001) compared with that found in healthy volunteers (2.5 ± 1.11 pg/mL). Moreover, there was a tendency toward higher serum concentrations of IL-17 in patients with more advanced disease (P = .005). Disease duration; patient sex, age, and body mass index; and smoking habits were not determining factors for IL-17 serum concentration. LIMITATIONS: Hospital-based study population was a limitation, as was a lack of posttreatment assessment. CONCLUSION: In light of our findings and literature on increased expression of IL-17 in HS lesions, evaluating the clinical effectiveness of using anti-IL-17 agents in the treatment of patients with HS is justified.
Authors: Sylke Schneider-Burrus; Athanasia Tsaousi; Sebastian Barbus; Johannes Huss-Marp; Katrin Witte; Kerstin Wolk; Björn Fritz; Robert Sabat Journal: Front Med (Lausanne) Date: 2021-04-27
Authors: Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin Journal: J Am Acad Dermatol Date: 2019-03-11 Impact factor: 15.487
Authors: Kristina Navrazhina; Sandra Garcet; Juana Gonzalez; David Grand; John W Frew; James G Krueger Journal: J Invest Dermatol Date: 2021-03-22 Impact factor: 7.590